ARS Pharmaceuticals, Inc. — Director's Dealing 2023

Jan 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2023-01-03

Reporting Person: Chakma Justin (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-03	Stock option (right to buy)	$8.42	A	165000	Acquired	2033-01-02	Common Stock (165000)	Direct

Footnotes

F1: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.